EBON (Ebang International Holdings Inc. Class A Ordinary Shares) Stock Analysis - Hedge Fund Holdings

Ebang International Holdings Inc. Class A Ordinary Shares (EBON) is a publicly traded Technology sector company. As of May 21, 2026, EBON trades at $1.99 with a market cap of $13.06M and a P/E ratio of 0.00. EBON moved +0.00% today. Year to date, EBON is -38.21%; over the trailing twelve months it is -45.81%. Its 52-week range spans $1.61 to $10.94. Rallies surfaces EBON's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns EBON stock?

Hedge funds tracked by Rallies that own EBON include Renaissance Technologies. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Ebang International Holdings Inc. Class A Ordinary Shares.

EBON Key Metrics

Key financial metrics for EBON
MetricValue
Price$1.99
Market Cap$13.06M
P/E Ratio0.00
EPS$0.00
Dividend Yield0.00%
52-Week High$10.94
52-Week Low$1.61
Volume16
Avg Volume0
Revenue (TTM)$0
Net Income$0
Gross Margin0.00%

Top Hedge Funds Holding EBON

  • Renaissance Technologies holds 55.03K shares of EBON, changed +18.05% as of Dec 31, 2024.

Latest EBON News

EBON Analyst Consensus

EBON analyst coverage data. Average price target: $0.00.

Common questions about EBON

Who owns EBON stock?
Hedge funds tracked by Rallies that own EBON include Renaissance Technologies. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Ebang International Holdings Inc. Class A Ordinary Shares.
Does Rallies show 13F holders for EBON?
Yes. Rallies tracks hedge fund and 13F ownership data for EBON, including fund names, share counts, latest tracked quarter, and position changes when available.
Is EBON research on Rallies investment advice?
No. Rallies provides research, data, and educational context for EBON. It does not provide personalized investment advice.
EBON

EBON